Recurrent Ameloblastoma of the Jaws—A Review of 22 Cases

Jo, Daramola; Ha, Ajagbe; Jo, Oluwasanmi

doi:10.1097/00006534-198005000-00006

Cited by 40 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…More than 50% of recurrences occur within 5 years of the primary surgical intervention [ 3 ]. However, sporadic reports of recurrences at 20, 30 and 45 years have been reported in the literature [ 79 – 82 ]. Of note, higher recurrence rate is reported in granular and follicular histological subtypes [ 3 ].…”

Section: Discussionmentioning

confidence: 99%

Establishing the Natural History and Growth Rate of Ameloblastoma with Implications for Management: Systematic Review and Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

BackgroundAmeloblastoma is the second most common odontogenic tumor, known to be slow-growing, persistent, and locally aggressive. Recent data suggests that ameloblastoma is best treated with wide resection and adequate margins. Following primary excision, bony reconstruction is often necessary for a functional and aesthetically satisfactory outcome, making early diagnosis paramount. Despite earlier diagnosis potentially limiting the extent of resection and reconstruction, an understanding of the growth rate and natural history of ameloblastoma has been notably lacking from the literature.MethodA systematic review of the literature was conducted by reviewing relevant articles from PubMed and Web of Science databases. Each article’s level of evidence was formally appraised according to the Centre of Evidence Based Medicine (CEBM), with data from each utilized in a meta-analysis of growth rates for ameloblastoma.ResultsLiterature regarding the natural history of ameloblastoma is limited since the tumor is immediately acted upon at its initial detection, unless the patient voluntarily refuses a surgical intervention. From the limited data, it is derived that the highest estimated growth rate is associated with solid, multicystic type and the lowest rate with peripheral ameloblastomas. After meta-analysis, the calculated mean specific grow rate is 87.84% per year.ConclusionThe growth rate of ameloblastoma has been demonstrated, offering prognostic and management information, particularly in cases where a delay in management is envisaged.

show abstract

Section: Discussionmentioning

confidence: 99%

Establishing the Natural History and Growth Rate of Ameloblastoma with Implications for Management: Systematic Review and Meta-Analysis

et al. 2015

View full text Add to dashboard Cite

show abstract

“…[5][6][7][8][9][10] Ameloblastomas also tend to recur many years after conservative treatment, ostensibly due to the lack of margin control with these procedures. [11][12][13][14] Currently, intraoperative tumor evaluation methods are lacking, especially in intraosseous tumors, resulting in positive margins in approximately 30% of head and neck cancer resections. 15 During surgery, tumor margins are typically assessed grossly by visual inspection and palpation.…”

Section: Introductionmentioning

confidence: 99%

Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study

Morlandt

Moore

Johnson

et al. 2020

Journal of Oral and Maxillofacial Surgery

View full text Add to dashboard Cite

Purpose: Fluorescently labeled epidermal growth factor receptor (EGFR) antibodies can successfully identify microscopic tumors in multiple in vivo models of human cancers with limited toxicity. This study demonstrates the ability of fluorescently labeled anti-EGFR, cetuximab-IRDye800, to localize to ameloblastoma tumor cells in vitro and in vivo.Material and Methods: EGFR expression in ameloblastoma cells was confirmed by qRT-PCR and immunohistochemistry. Primary ameloblastoma cells were labeled in vitro with cetuximab-IRDye800 or non-specific IgG-IRDye800. An in vivo patient-derived xenograft model of ameloblastoma was developed: tumor tissue from three patients was implanted subcutaneously into immunocompromised mice, animals received intravenous injection of cetuximab-IRDye800 or IgG-IRDye800, and were imaged to detect infrared fluorescence using a LI-COR Pearl imaging

show abstract

“…In their study, Muller and Slootweg 11 reported a 73% recurrence rate in those patients treated conservatively. Similarly, Daramola et al 12 noted that 18 of the 22 recurrent ameloblastomas seen in their institution were caused by inadequate removal by curettage, whereas Ueno et al 9 reported an 8.7%o recurrence rate in 23 patients treated with radical excision.…”

Section: Discussionmentioning

confidence: 95%

Case Report Editor: Unusual otolaryngic presentations of ameloblastoma

Martinez¹,

Schmidt²,

Moses³

et al. 1999

Otolaryngol.--head neck surg.

View full text Add to dashboard Cite

Ameloblastomas have been the source of much intrigue to both pathologists and surgeons: to pathologists because of their variable histologic appearance and to surgeons for their unrelenting ability to recur. Much of the literature has centered around discussions of origin, behavior, various classification systems, and surgical treatments for ameloblastomas. Controversy exists concerning the cell of origin of the ameloblastoma, resulting in the appearance of more than 50 names for this tumor in the literature.Amelo is old French for enamel, although this tumor contains no enamel. It is thought to originate from tissue that differentiates into the enamel organ. Blastoma, meaning tumor of one type, is an oversimplification of this histologically diverse tumor. The World Health Organization in 1971 defined ameloblastomas as benign but locally invasive neoplasms consisting of proliferating odontogenic epithelium lying in a fibrous stroma. However, cases of both ameloblastic carcinoma and metastasizing ameloblastoma have been reported. Gold 1 defined ameloblastomas as low-grade malignant basaloid neoplasms with a variable range of histologic patterns, clinical forms, and behavior. He also compared ameloblastomas to basal cell carcinomas with regard to their biologic behavior.Ameloblastomas are the most common odontogenic neoplasm and yet comprise only 1% of all tumors of the maxilla and mandible. 2 Males and females are affected equally, with most presenting during the fourth decade of life. 3,4 The mandible is the site of origin in 80% of cases, whereas approximately 20% arise in the maxilla. 4 We present 2 unusual cases of maxillary ameloblastoma to illustrate that these uncommon neoplasms may present in a variety of ways and that their presentation, either as a primary tumor or as a metastasis, may mimic much more common disease processes seen by the otolaryngologist. CASE REPORTSCase 1. An 81-year-old woman went to her dentist with left maxillary swelling. Surgical excision by an oral surgeon was performed in November 1992. Increasing symptoms of left maxillary fullness prompted a biopsy in early June 1993, which revealed recurrent ameloblastoma and led to a referral to the senior author (W.M.K.). Examination revealed an extensive lesion replacing the maxilla with erosion superiorly through the orbital floor and involvement of the ethmoid sinus. The lesion extended into the buccal mucosa and into the pterygomaxillary space. A left medial maxillectomy was performed in July 1993. Pathologic evaluation confirmed the diagnosis (Fig 1). In December 1993 she had recurrent tumor removed, followed by postoperative radiation therapy to 5940 cGy. She did well until January 1995, when she went to the emergency department in acute airway distress. She was taken to the operating room for direct laryngoscopy, and a large mass, believed to represent granulation tissue, was noted coming off the posterior commissure, narrowing the subglottic lumen by approximately 40%. With endoscopic visualization the lesion was completely excised...

show abstract

Recurrent Ameloblastoma of the Jaws—A Review of 22 Cases

Cited by 40 publications

References 0 publications

Establishing the Natural History and Growth Rate of Ameloblastoma with Implications for Management: Systematic Review and Meta-Analysis

Establishing the Natural History and Growth Rate of Ameloblastoma with Implications for Management: Systematic Review and Meta-Analysis

Fluorescently Labeled Cetuximab-IRDye800 for Guided Surgical Excision of Ameloblastoma: A Proof of Principle Study

Case Report Editor: Unusual otolaryngic presentations of ameloblastoma

Contact Info

Product

Resources

About